| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司是集化学合成、生物发酵核苷（酸）类原料药及医药中间体的研发、生产及销售为一体的高新技术企业，在国内核苷（酸）类原料药及医药中间体产品的研制、生产等方面具有较强实力。公司在国内核苷（酸）类原料药及医药中间体的研发领域具备起步早、规模大、品种全等优势，并形成了从基础产品到高端产品阶梯性的较为完整产品链。经过近二十年的发展和积累，公司形成了嘧啶系列、嘌呤系列、核苷酸系列、核苷系列等多个系列核苷（酸）类产品，包括胞磷胆碱钠、利巴韦林、肌苷、阿昔洛韦、胞嘧啶、5-氟胞嘧啶、胞苷等原料药及医药中间体，主要涵盖抗病毒、抗肿瘤和神经系统用药领域。 公司始终以“研发创新”为核心，高度重视对产品研发的投入和自身研发综合实力的提高，已建成“河南省博士后研发基地”、“国家博士后科研工作站”，先后被认定为“国家高技术产业示范工程”、“河南省高新技术特色产业基地首批骨干企业”、“河南省企业技术中心”、“河南省核苷工程技术研究中心”，先后获得河南省科学技术进步一等奖、国家科学技术进步二等奖等重大科技奖项，多项产品入选“国家重点新产品”、“国家火炬计划项目”。 | ||||||||||||||||||||||||
| Main Business | 化学合成、生物发酵核苷（酸）类原料药及医药中间体的研发、生产和销售。 | ||||||||||||||||||||||||
| Legal Representative | 杨西宁 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 杨钰华 | ||||||||||||||||||||||||
| Solicitors | 北京市康达律师事务所 | ||||||||||||||||||||||||
| Auditors | 中审众环会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0373-6351918 | ||||||||||||||||||||||||
| Fax No | 0373-6351918 | ||||||||||||||||||||||||
| Website | www.tuoxinpharm.com | ||||||||||||||||||||||||
| tuoxinyyh@163.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 27/10/2021 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 1.930 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.250 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 12.670 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 4.184B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |